EUVIMEDEUVIMED entdecken
Crossref

Re-Profiling of US-FDA Approved Drugs for COVID-19 by In-silico Studies

Akash Parab, Dr Gaganjyot Kaur, Abhishek Sharma, Gursewak Bhuller, Sharvari Chitnis, Ankit Chindaliya, Mayur Weta

Journal of Bioinformatics and Systems Biology · 2021

DOI: 10.26502/jbsb.5107021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Bioinformatics and Systems Biology, 2021. Verfasst von Akash Parab und 6 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Parab, A., Kaur, D. G., Sharma, A., Bhuller, G., Chitnis, S., Chindaliya, A., & Weta, M. (2021). Re-Profiling of US-FDA Approved Drugs for COVID-19 by In-silico Studies. Journal of Bioinformatics and Systems Biology. https://doi.org/10.26502/jbsb.5107021

Vancouver

Parab A, Kaur DG, Sharma A, Bhuller G, Chitnis S, Chindaliya A, et al. Re-Profiling of US-FDA Approved Drugs for COVID-19 by In-silico Studies. Journal of Bioinformatics and Systems Biology. 2021. doi:10.26502/jbsb.5107021

BibTeX
@article{Parab2021,
  author = {Parab, Akash and Kaur, Dr Gaganjyot and Sharma, Abhishek and Bhuller, Gursewak and Chitnis, Sharvari and Chindaliya, Ankit and Weta, Mayur},
  title = {Re-Profiling of US-FDA Approved Drugs for COVID-19 by In-silico Studies},
  journal = {Journal of Bioinformatics and Systems Biology},
  year = {2021},
  doi = {10.26502/jbsb.5107021}
}
Kostenlos starten →